David Belyea is an Ophthalmology physician. OpenAlex indexes 56 publications with 665 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2226 Nelson Hwy Ste 200
Chapel Hill, NC 275179638
Telephone
984-974-2020Provider last certified this registry record 9 Oct 2025.
Clinical trials
- Effect of Sunflower Lecithin Supplementation on Meibomian Gland Function in Adults With Dry Eye Disease
Sponsor: George Washington University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AbbVie Inc.Program year20231 payment
- Oyster Point Pharma, Inc.Program year20231 payment
- Oyster Point Pharma, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
85.5%Prostaglandin Analog38.8%Latanoprost85%Travoprost12%Lumigan3%Part D<11 patientsCarbonic Anhydrase Inhibitor21%Dorzolamide-Timolol65%Dorzolamide Hcl23%Brinzolamide13%Part D≥58 patients+ 3 more classes in this area
Cardiovascular
11.5%Beta blocker11.5%Timolol Maleate100%Part D≥48 patientsMusculoskeletal
1.5%Cyclooxygenase Inhibitor1.5%Ketorolac Tromethamine100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of the COVID-19 Pandemic on Medicare Reimbursement and Glaucoma Procedure Utilization
Ophthalmology Glaucoma
2025 - Pseudophakic Pupillary Block due to the Capsular Bag Intraocular Lens Implant Located in the Sulcus: A Case Report
Case Reports in Ophthalmology
2024 - Patient Demand for Ophthalmologists in the United States: A Google Trends Analysis
Ophthalmic Epidemiology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”